New insider activity at Labcorp Holdings ( (LH) ) has taken place on February 26, 2026.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Brian J. Caveney, EVP, President of Early Development, Chief Medical Officer, and Chief Scientific Officer at Labcorp Holdings, has reported a notable stock transaction, selling 1,500 shares of Labcorp Holdings stock in a move valued at $429,450. This insider sale sheds light on recent executive activity within the company and may draw attention from investors tracking leadership’s trading decisions.
Recent Updates on LH stock
Labcorp’s shares reacted to Q4 results that showed solid revenue, margin and EPS growth, but slightly missed consensus sales. Analysts’ updated views appear driven by confidence in sustained diagnostics and central lab strength, robust backlog and free cash flow, and the company’s detailed 2026 growth outlook despite early‑development softness and higher capex.
Spark’s Take on LH Stock
According to Spark, TipRanks’ AI Analyst, LH is a Outperform.
The score is driven by improving operational outlook and supportive technical momentum (price above key moving averages with positive MACD), partly offset by only solid—not exceptional—financial consistency (margin and FCF variability) and a relatively high P/E with a modest dividend yield.
To see Spark’s full report on LH stock, click here.
More about Labcorp Holdings
YTD Price Performance: 12.72%
Average Trading Volume: 725,583
Technical Sentiment Signal: Buy
Current Market Cap: $23.8B